83 research outputs found
Modeling the Effects of Multiple Myeloma on Kidney Function
Multiple myeloma (MM), a plasma cell cancer, is associated with many health
challenges, including damage to the kidney by tubulointerstitial fibrosis. We
develop a mathematical model which captures the qualitative behavior of the
cell and protein populations involved. Specifically, we model the interaction
between cells in the proximal tubule of the kidney, free light chains, renal
fibroblasts, and myeloma cells. We analyze the model for steady-state solutions
to find a mathematically and biologically relevant stable steady-state
solution. This foundational model provides a representation of dynamics between
key populations in tubulointerstitial fibrosis that demonstrates how these
populations interact to affect patient prognosis in patients with MM and renal
impairment.Comment: Included version of model without tumor with steady-state analysis,
corrected equations for free light chains and renal fibroblasts in model with
tumor to reflect steady-state analysis, updated abstract, updated and added
reference
The Role of Osteocytes in Targeted Bone Remodeling: A Mathematical Model
Until recently many studies of bone remodeling at the cellular level have
focused on the behavior of mature osteoblasts and osteoclasts, and their
respective precursor cells, with the role of osteocytes and bone lining cells
left largely unexplored. This is particularly true with respect to the
mathematical modeling of bone remodeling. However, there is increasing evidence
that osteocytes play important roles in the cycle of targeted bone remodeling,
in serving as a significant source of RANKL to support osteoclastogenesis, and
in secreting the bone formation inhibitor sclerostin. Moreover, there is also
increasing interest in sclerostin, an osteocyte-secreted bone formation
inhibitor, and its role in regulating local response to changes in the bone
microenvironment. Here we develop a cell population model of bone remodeling
that includes the role of osteocytes, sclerostin, and allows for the
possibility of RANKL expression by osteocyte cell populations. This model
extends and complements many of the existing mathematical models for bone
remodeling but can be used to explore aspects of the process of bone remodeling
that were previously beyond the scope of prior modeling work. Through numerical
simulations we demonstrate that our model can be used to theoretically explore
many of the most recent experimental results for bone remodeling, and can be
utilized to assess the effects of novel bone-targeting agents on the bone
remodeling process
Precursors of extreme increments
We investigate precursors and predictability of extreme increments in a time
series. The events we are focusing on consist in large increments within
successive time steps. We are especially interested in understanding how the
quality of the predictions depends on the strategy to choose precursors, on the
size of the event and on the correlation strength. We study the prediction of
extreme increments analytically in an AR(1) process, and numerically in wind
speed recordings and long-range correlated ARMA data. We evaluate the success
of predictions via receiver operator characteristics (ROC-curves). Furthermore,
we observe an increase of the quality of predictions with increasing event size
and with decreasing correlation in all examples. Both effects can be understood
by using the likelihood ratio as a summary index for smooth ROC-curves
Inhibition of Geranylgeranyl Diphosphate Synthase is a Novel Therapeutic Strategy for Pancreatic Ductal Adenocarcinoma
Rab proteins play an essential role in regulating intracellular membrane trafficking processes. Rab activity is dependent upon geranylgeranylation, a post-translational modification that involves the addition of 20-carbon isoprenoid chains via the enzyme geranylgeranyl transferase (GGTase) II. We have focused on the development of inhibitors against geranylgeranyl diphosphate synthase (GGDPS), which generates the isoprenoid donor (GGPP), as anti-Rab agents. Pancreatic ductal adenocarcinoma (PDAC) is characterized by abnormal mucin production and these mucins play important roles in tumor development, metastasis and chemo-resistance. We hypothesized that GGDPS inhibitor (GGDPSi) treatment would induce PDAC cell death by disrupting mucin trafficking, thereby inducing the unfolded protein response pathway (UPR) and apoptosis. To this end, we evaluated the effects of RAM2061, a potent GGDPSi, against PDAC. Our studies revealed that GGDPSi treatment activates the UPR and triggers apoptosis in a variety of human and mouse PDAC cell lines. Furthermore, GGDPSi treatment was found to disrupt the intracellular trafficking of key mucins such as MUC1. These effects could be recapitulated by incubation with a specific GGTase II inhibitor, but not a GGTase I inhibitor, consistent with the effect being dependent on disruption of Rab-mediated activities. In addition, siRNA-mediated knockdown of GGDPS induces upregulation of UPR markers and disrupts MUC1 trafficking in PDAC cells. Experiments in two mouse models of PDAC demonstrated that GGDPSi treatment significantly slows tumor growth. Collectively, these data support further development of GGDPSi therapy as a novel strategy for the treatment of PDAC
The Peptide–Drug Conjugate Melflufen Modulates the Unfolded Protein Response of Multiple Myeloma and Amyloidogenic Plasma Cells and Induces Cell Death
Immunoglobulin light-chain (AL) amyloidosis is a rare disease caused by clonal plasma cell secretion of misfolded light chains that assemble as toxic amyloid fibrils, depositing in vital organs including the heart and kidneys, causing organ dysfunction. Plasma cell–directed therapeutics are expected to reduce production of toxic light chain by eliminating amyloidogenic cells in bone marrow, thereby diminishing amyloid fibril deposition and providing the potential for organ recovery. Melphalan flufenamide (melflufen) is a first-in-class peptide–drug conjugate that targets aminopeptidases and rapidly releases alkylating agents inside tumor cells. Melflufen is highly lipophilic, permitting rapid uptake by cells, where it is enzymatically hydrolyzed by aminopeptidases, resulting in intracellular accumulation of the alkylating agents, including melphalan. Previous data demonstrating sensitivity of myeloma cells to melflufen suggest that the drug might be useful in AL amyloidosis. We describe the effects of melflufen on amyloidogenic plasma cells in vitro and ex vivo, demonstrating enhanced cytotoxic effects in comparison to melphalan, as well as novel mechanisms of action through the unfolded protein response (UPR) pathway. These findings provide evidence that melflufen-mediated cytotoxicity extends to amyloidogenic plasma cells, and support the rationale for the evaluation of melflufen in patients with AL amyloidosis.Peer reviewe
Targeting the Isoprenoid Biosynthetic Pathway in Multiple Myeloma
Multiple myeloma (MM) is a plasma cell malignancy for which there is currently no cure. While treatment options for MM have expanded over the last two decades, all patients will eventually become resistant to current therapies. Thus, there is an urgent need for novel therapeutic strategies to treat MM. The isoprenoid biosynthetic pathway (IBP) is responsible for the post-translational modification of proteins belonging to the Ras small GTPase superfamily, such as Ras, Rho and Rab family members. Given the important roles these GTPase proteins play in various cellular processes, there is significant interest in the development of inhibitors that disturb their prenylation and consequently their activity in MM cells. Numerous preclinical studies have demonstrated that IBP inhibitors have anti-MM effects, including the induction of apoptosis in MM cells and inhibition of osteoclast activity. Some IBP inhibitors have made their way into the clinic. For instance, nitrogenous bisphosphonates are routinely prescribed for the management MM bone disease. Other IBP inhibitors, including statins and farnesyltransferase inhibitors, have been evaluated in clinical trials for MM, while there is substantial preclinical investigation into geranylgeranyl diphosphate synthase inhibitors. Here we discuss recent advances in the development of IBP inhibitors, assess their mechanism of action and evaluate their potential as anti-MM agents
Targeting the Isoprenoid Biosynthetic Pathway in Multiple Myeloma
Multiple myeloma (MM) is a plasma cell malignancy for which there is currently no cure. While treatment options for MM have expanded over the last two decades, all patients will eventually become resistant to current therapies. Thus, there is an urgent need for novel therapeutic strategies to treat MM. The isoprenoid biosynthetic pathway (IBP) is responsible for the post-translational modification of proteins belonging to the Ras small GTPase superfamily, such as Ras, Rho and Rab family members. Given the important roles these GTPase proteins play in various cellular processes, there is significant interest in the development of inhibitors that disturb their prenylation and consequently their activity in MM cells. Numerous preclinical studies have demonstrated that IBP inhibitors have anti-MM effects, including the induction of apoptosis in MM cells and inhibition of osteoclast activity. Some IBP inhibitors have made their way into the clinic. For instance, nitrogenous bisphosphonates are routinely prescribed for the management MM bone disease. Other IBP inhibitors, including statins and farnesyltransferase inhibitors, have been evaluated in clinical trials for MM, while there is substantial preclinical investigation into geranylgeranyl diphosphate synthase inhibitors. Here we discuss recent advances in the development of IBP inhibitors, assess their mechanism of action and evaluate their potential as anti-MM agents
- …